Management of pancreatic cancer: Current status and future directions
Author:
- 1 December 2009
- journal article
- review article
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 71 (6) , 368-372
Abstract
Despite advances in surgery and adjuvant therapy pancreatic ductal adenocarcinoma has a dismal prognosis. Surgical resection with negative margins remains the mainstay of treatment, and results can be improved with neoadjuvant therapy when the lesion is of borderline resectability. Extended lymphadenectomy has no role in improving survival, but may worsen quality of life. Venous resection can be performed if it helps to achieve an R0 resection, but arterial resection is not justified. A host of newer agents, both cytotoxic and targeted, are being evaluated. The article summarizes the critical issues and looks ahead to the future.Keywords
This publication has 30 references indexed in Scilit:
- Novel agents for the treatment of adenocarcinoma of the pancreasExpert Review of Anticancer Therapy, 2009
- Margin Clearance and Outcome in Resected Pancreatic CancerJournal of Clinical Oncology, 2009
- Surgical Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus StatementAnnals of Surgical Oncology, 2009
- Crossing the Rubicon: When Pancreatic Resection with Curative Intent Ends in an R2 StatusAnnals of Surgical Oncology, 2009
- Feasibility of a Randomized Trial of Extended Lymphadenectomy for Pancreatic CancerArchives of Surgery, 2005
- Pancreaticoduodenectomy With or Without Distal Gastrectomy and Extended Retroperitoneal Lymphadenectomy for Periampullary Adenocarcinoma, Part 2Annals of Surgery, 2002
- Standard Versus Extended Lymphadenectomy Associated With Pancreatoduodenectomy in the Surgical Treatment of Adenocarcinoma of the Head of the PancreasAnnals of Surgery, 1998
- Survival After PancreatoduodenectomyAnnals of Surgery, 1990
- Lymph node involvement in carcinoma of the head of the pancreas areaCancer, 1978
- Adenocarcinoma of the PancreasAnnals of Surgery, 1975